In this Book

buy this book Buy This Book in Print
summary

A pill can strengthen national security? The suggestion may seem odd, but many states around the world believe precisely that. Confronted with pandemics, bioterrorism, and emerging infectious diseases, governments are transforming their security policies to include the proactive development, acquisition, stockpiling, and mass distribution of new pharmaceutical defenses. What happens—politically, economically, and socially—when governments try to protect their populations with pharmaceuticals? How do competing interests among states, pharmaceutical companies, regulators, and scientists play out in the quest to develop new medical countermeasures? And do citizens around the world ultimately stand to gain or lose from this pharmaceuticalization of security policy?

Stefan Elbe explores these complex questions in Pandemics, Pills, and Politics, the first in-depth study of the world’s most prominent medical countermeasure, Tamiflu. Taken by millions of people around the planet in the fight against pandemic flu, Tamiflu has provoked suspicions about undue commercial influence in government decision-making about stockpiles. It even found itself at the center of a prolonged political battle over who should have access to the data about the safety and effectiveness of medicines.

Pandemics, Pills, and Politics shows that the story of Tamiflu harbors deeper lessons about the vexing political, economic, legal, social, and regulatory tensions that emerge as twenty-first-century security policy takes a pharmaceutical turn. At the heart of this issue, Elbe argues, lies something deeper: the rise of a new molecular vision of life that is reshaping the world we live in.

Table of Contents

  1. Cover Page
  2. open access View | Download |
  1. Title Page
  2. open access View | Download |
  1. Copyright Page
  2. open access View | Download |
  1. Dedication
  2. open access View | Download |
  1. Epigraphs
  2. open access View | Download |
  1. Contents
  2. pp. ix-x
  3. open access View | Download |
  1. Preface
  2. pp. xi-xii
  3. open access View | Download |
  1. Acknowledgments
  2. pp. xiii-xiv
  3. open access View | Download |
  1. List of Abbreviations
  2. open access View | Download |
  1. 1. Encapsulating Security: Pharmaceutical Defenses against Biological Danger
  2. pp. 1-28
  3. open access View | Download |
  1. Part One: The Development Challenges
  1. 2. Discovering a Virus’s Achilles Heel: Flu Fighting at the Molecular Scale
  2. pp. 31-53
  3. open access View | Download |
  1. 3. The Pill Always Wins: Gilead Sciences, Roche, and the Birth of Tamiflu
  2. pp. 54-76
  3. open access View | Download |
  1. Part Two: The Acquisition Challenges
  1. 4. What a Difference a Day Makes: The Margin Call for Regulatory Agencies
  2. pp. 79-105
  3. open access View | Download |
  1. 5. Virtual Blockbuster: Bird Flu and the Pandemic of Preparedness Planning
  2. pp. 106-133
  3. open access View | Download |
  1. Part Three: The Deployment Challenges
  1. 6. In the Eye of the Storm: Global Access, Generics, and Intellectual Property
  2. pp. 137-162
  3. open access View | Download |
  1. 7. “Ode to Tamiflu”: Side Effects, Teenage “Suicides,” and Corporate Liabilities
  2. pp. 163-183
  3. open access View | Download |
  1. 8. Data Backlash: Roche and Cochrane Square Up over Clinical Trial Data
  2. pp. 184-210
  3. open access View | Download |
  1. 9. “To Boldly Go …”: Pharmaceutical Enterprises and Global Health Security
  2. pp. 211-232
  3. open access View | Download |
  1. Epilogue: Pharmaceuticals, Security, and Molecular Life
  2. pp. 233-236
  3. open access View | Download |
  1. References
  2. pp. 237-253
  3. open access View | Download |
  1. Index
  2. pp. 255-261
  3. open access View | Download |

Additional Information

ISBN
9781421428772
Print ISBN
9781421425580
MARC Record
OCLC
1035556715
Launched on MUSE
2018-07-22
Language
English
Open Access
Y
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.